Clinical Trials Logo

Cholangiocarcinoma clinical trials

View clinical trials related to Cholangiocarcinoma.

Filter by:

NCT ID: NCT03003065 Recruiting - Cholangiocarcinoma Clinical Trials

Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers

PDT
Start date: January 2014
Phase: Phase 2
Study type: Interventional

In this study, we hope to evaluate the safety of PDT using temoporfin plus endoscopic stents in patients with inoperable bile duct cancers. In addition as a preliminary study we sought to determine if the treatment can reduce tumor volume in the short term.

NCT ID: NCT02999672 Recruiting - Clinical trials for Bladder Cancer, Pancreas Cancer, Cholangiocellular Carcinoma

A Phase II Study to Evaluate the Efficacy, and Safety of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer (UBC) or Pancreas/Cholangio Cancer (Kameleon Study)

Start date: December 2016
Phase: Phase 2
Study type: Interventional

This multicenter, non-randomized, Phase II, single agent study will assess the efficacy, and safety of trastuzumab emtansine in participants with HER2-positive (immunohistochemistry [IHC]3+ in greater than or equal to [>/=] 30 percent [%] of tumor cells) locally advanced or metastatic UBC or metastatic pancreas/cholangio cancer. Participants must have received at least one prior (for bladder cancer platinum-based) treatment for inoperable, locally advanced or metastatic tumor. Participants will receive intravenous (IV) infusion (infusion duration=90 minutes [mins]) of trastuzumab emtansine until unacceptable toxicity, withdrawal of consent, disease progression (PD), or death, whichever occurs first.

NCT ID: NCT02994251 Not yet recruiting - Clinical trials for Unresectable Intrahepatic Cholangiocarcinoma

A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma

Start date: December 2016
Phase: Phase 2
Study type: Interventional

The study will be a single-center, single-arm, Phase II study of gemcitabine and cisplatin in combination with conventional trans-arterial chemoembolization therapy in adult patients with advanced ICC. 25 patients will be enrolled over the course of 2 years, with an additional 1.5 years for patient follow-up.

NCT ID: NCT02989857 Not yet recruiting - Clinical trials for Advanced Cholangiocarcinoma

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)

ClarIDHy
Start date: December 2016
Phase: Phase 3
Study type: Interventional

Study AG120-C-005 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of orally administered AG-120. Subjects, all personnel involved in the evaluation of subjects' response to treatment (e.g., Investigators, study coordinators, study pharmacists), and designated Sponsor team members will be blinded to study treatment. Subjects are required to have a histologically-confirmed diagnosis of IDH1 gene-mutated cholangiocarcinoma that is not eligible for curative resection, transplantation, or ablative therapies prior to enrollment.IDH1 mutation testing will be performed at participating investigative sites. Subjects must have progression of disease and have received at least 1 but not more than 2 prior treatment regimens for advanced disease (nonresectable or metastatic). All subjects must have received either a gemcitabine or a 5 fluorouracil (5-FU) based chemotherapy regimen.

NCT ID: NCT02982720 Not yet recruiting - Clinical trials for Advanced Cholangiocarcinoma

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

Start date: December 2016
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, multicenter Phase II safety and efficacy study of combination therapy with pembrolizumab and PEG-Intron (Peginterferon alpha-2b) in patients with advanced cholangiocarcinoma who have progressed on or cannot tolerate frontline chemotherapy. PEG-Intron will be administered to patients as a 3ug/kg (subject to possible dose modification) subcutaneous injection weekly, while pembrolizumab will be administered as a 200mg IV infusion once every three weeks, starting on week 4 (at the same time as the 4th dose of PEG-Intron). This trial design provides an initial window (3 weeks) to evaluate the effect of PEG-Intron alone on tumor microenvironment in comparison to that of prior therapy: a biopsy prior to treatment will be collected, followed by a, repeat tumor biopsies collected while the patients receive PEG-Intron. Tumor tissue will be collected and analyzed as described in the next paragraph.

NCT ID: NCT02955771 Recruiting - Clinical trials for Hilar Cholangiocarcinoma

Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma

Start date: October 2016
Phase: Phase 2
Study type: Interventional

This is a multi-center, randomized, controlled, open-label, phase IIa clinical study.The study will observe the efficacy and safety of Deuteporfin photodynamic therapy in addition to stenting compared to stenting alone in patients with unresectable advanced Perihilar Cholangiocarcinoma.

NCT ID: NCT02924376 Recruiting - Cholangiocarcinoma Clinical Trials

Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy

Start date: October 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is evaluate the efficacy of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.

NCT ID: NCT02917759 Recruiting - Clinical trials for Hepatocellular Carcinoma

Liver and Biliary Tumor Tissue Registry

Start date: February 2014
Phase: N/A
Study type: Observational [Patient Registry]

Patients having surgery to remove a liver or biliary tissue mass will have a tissue sample collected and stored for future research. A blood sample may also be collected at the time of enrollment.

NCT ID: NCT02893085 Completed - Clinical trials for Cholangiocarcinoma, Cancer of the Head of the Pancreas

Pancreatico-biliary Tumor Mutation Profiling in Bile Samples

ONCOBIL
Start date: September 2015
Phase: N/A
Study type: Observational

The differential diagnosis between benign and malignant bile duct strictures is a difficult and demanding task for clinicians. Clinical, biochemical, and radiological characteristics of malignant biliary strictures are non-specific and tissue diagnosis is difficult to obtain preoperatively. For this reason, there is a need for the development of new diagnostic modalities. Of particular interest is the quest of tumor markers secreted or shed in bile by tumor cells developing in the biliary tract. In addition, patient's tumor molecular profile is the basis for selecting personalized therapy. Cholangiocarcinomas are characterized by a large genetic heterogeneity. The most frequent mutations are TP53, KRAS, BRAF, EGFR, MET, NRAS, PIK3CA, ERBB2, SMAD4, FBXW7, ARID1A, PBRM1, BAP1 et IDH1/2. In the case of pancreatic cancers, the most frequent are KRAS mutation detected in 90 % of the patients and CDKN2A, SMAD4, TGFBR1, TGFBR2, ATM, BRCA2, MLL2, MLL3, KDM6A, ARID1A, ARID1B, SMARC1, GNAS and RNF43 mutations. It is well established that KRAS and P53 mutations can be detected in bile samples from patients with biliary strictures related to cholangiocarcinoma and cancer of the head of the pancreas. The main objective is to determine if bile sample analysis from patients with malignant biliary stricture may allow to identify tumor mutation profile and determine tumor genotype. A secondary objective is to evaluate the diagnostic value of Vascular Endothelial Growth Factor (VEGF) and metallo-proteinases (MMPs) levels in bile samples. Tumor genotyping will be performed in bile samples (supernatant and cell pellet) and tumor tissues in a series of 10 patients surgically treated for malignant biliary stricture related to cholangiocarcinoma or cancer of the head of the pancreas. The biochemical markers, VEGF and MMPs, will be assessed in bile samples obtained during endoscopic retrograde cholangiopancreatography in 50 patients with malignant biliary stricture and 50 patients treated for benign biliary diseases.

NCT ID: NCT02881554 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery

Start date: October 2016
Phase: N/A
Study type: Interventional

This pilot trial studies how well single photon emission computed tomography (SPECT)/computed tomography (CT) with technetium Tc-99m sulfur colloid works in measuring liver function in patients with liver cancer that has or has not spread to other place in the body who are undergoing radiation therapy or surgery. Diagnostic procedures, such as sulfur colloid SPECT/CT scans, may measure normal liver tissue before, during and after treatment and help doctors plan better treatment for liver cancer patients.